For full information, please ensure you read the patient information leaflet – this can be found in your pack or downloaded here.
Like all medicines, Movymia® (teriparatide) can cause side effects, although not everybody gets them.
The most common side effects are pain in limb (which may affect more than 1 in 10 people). Other common side effects (affecting up to 1 in 10 people) include feeling sick, headache and dizziness. If you become dizzy (light-headed) after your injection, you should sit or lie down until you feel better. If you do not feel better, you should call a doctor before you continue treatment. Cases of fainting have occured after teriparatide use.
If you have discomfort around the area of the injection such as redness of the skin, pain, swelling, itching, bruising or minor bleeding (which can occur in up to 1 in 10 people), this should clear up in a few days or weeks. Otherwise tell your doctor.
Rarely, patients may suffer allergic reactions consisting of breathlessness, swelling of the face, rash and chest pain. These reactions usually occur soon after injection. In rare cases, serious and potentially life-threatening allergic reactions including anaphylaxis can occur.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme web site or by searching for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Movymia® (teriparatide) may increase calcium in your blood or urine. Talk to your doctor before or while using Movymia® (teriparatide):
Some patients get dizzy or get a fast heartbeat after the first few doses of Movymia® (teriparatide). For the first doses, inject Movymia® (teriparatide) in a place where you can sit or lie down right away if you get dizzy.
The recommended treatment time of 24 months should not be exceeded.
Before inserting a cartridge in Movymia® (teriparatide) Pen write down the batch (Lot) number of the cartridge and its first injection date on a calendar. The date of first injection should also be recorded on the outer carton of Movymia® (teriparatide) (see the provided space on the box: {First use:}).
Movymia® (teriparatide) should not be used in growing adults.
Movymia® (teriparatide) should not be used in children and adolescents (aged less than 18 years).
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
This is important, because some medicines (e.g. digoxin/digitalis, a medicine used to treat heart disease) may interact with teriparatide.
Do not use Movymia® (teriparatide) if you are pregnant or breast-feeding. If you are a woman of child-bearing potential, you should use effective methods of contraception during use of Movymia® (teriparatide). If you become pregnant while using Movymia® (teriparatide), Movymia® (teriparatide) should be discontinued. Ask your doctor or pharmacist for advice before taking any medicine.
Some patients may feel dizzy after injecting Movymia® (teriparatide). If you feel dizzy you should not drive or use machines until you feel better.
This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially “sodium-free”.
The information on this site is suitable for and solely intended for UK patients prescribed this medicine following consultation with a UK healthcare professional. Are you a patient who has been prescribed this medicine by a UK healthcare professional?
Reporting of side effects. If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. ▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may experience. You can report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. Side effects should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164.
UK-MOVY-2aaa(1) | February 2023